Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study

Journal of Clinical Psychiatry

Volumn 74, Issue 2, 2013, Pages 170-179

  McEvoy, Joseph P ^a   Citrome, Leslie ^b   Hernandez, David ^c   Cucchiaro, Josephine ^c   Hsu, Jay ^c   Pikalov, Andrei ^c   Loebel, Antony ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENZATROPINE; BIPERIDEN; DIPHENHYDRAMINE; ESZOPICLONE; GLUCOSE; HERBACEOUS AGENT; HYPNOTIC AGENT; ILOPERIDONE; INSULIN; LAMOTRIGINE; LIPID; LITHIUM; LORAZEPAM; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PROLACTIN; PROPRANOLOL; QUETIAPINE; RISPERIDONE; TEMAZEPAM; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROATE SEMISODIUM; ZALEPLON; ZIPRASIDONE; ZOLPIDEM;

ADULT; AKATHISIA; ANXIETY; ANXIETY DISORDER; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-IV; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84874607585     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m07992     Document Type: Article

References (44)

1. Sunovion. Latuda (lurasidone). http://www.latuda.com/ LatudaPrescribingInformation.pdf. Revised April 2012. Updated May 2012. Accessed December 13, 2012.
2. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(6):829-836. doi:10.408/JCP.08m04905 PubMed
3. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapinecontrolled study. Am J Psychiatry. 2011;168(9):957-967. doi:10.176/api.ajp.201.1060907 PubMed
4. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2012. doi:10.107/s0213-012-2838-2 PubMed
5. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6(2):76-85. doi:10.371/CSRP.6.2.5 PubMed
6. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10(12):1917-1928. doi:10.1517/14656560903061309 PubMed
7. Faries DE, Ascher-Svanum H, Nyhuis AW, et al. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry. 2009;9(1):54. doi:10.186/1471-24X-9-54 PubMed
8. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17-29. doi:10.1093/oxfordjournals.schbul.a06920 PubMed (Pubitemid 34534747)
9. Citrome L. Interpreting and applying the CATIE results: with CATIE, context is key, when sorting out Phases 1, 1A, 1B, 2E, and 2T. Psychiatry (Edgmont). 2007;4(10):23-29. PubMed
10. Stroup TS, McEvoy JP, Ring KD, et al; Schizophrenia Trials Network. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison Of Antipsychotics for Metabolic Problems (CAMP). Am J Psychiatry. 2011;168(9):947-956. doi:10.176/api.ajp.201.101609 PubMed
11. Weiden PJ, Newcomer JW, Loebel AD, et al. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-994. doi:10.1038/sj.np.1301482 PubMed (Pubitemid 351367540)
12. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:534-537.
13. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39(11): 1172-1177. PubMed
14. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154(5):672-676. doi:10.192/bjp.154.5.672 PubMed (Pubitemid 19154942)
15. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212(S212):11-19. doi:10.1/j.160-047.1970. tb0206.x PubMed
16. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 1994.
17. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3(4):247-251. doi:10.1016/0920-964(90)905-R PubMed (Pubitemid 20228720)
18. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12): 1266-1277. doi:10.176/api.ajp.201.101704 PubMed
19. Voruganti LN, Awad AG. Personal Evaluation of Transitions in Treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56(1-2):37-46. doi:10.1016/S0920-964(01)0161- X PubMed (Pubitemid 34655466)
20. Browne G, Gafni A, Roberts J, et al. Approach to the Measurement of Costs (Expenditures) When Evaluating the Efficiency of Health and Social Programmes. Working Paper Series 92-12, System-Linked Research Unit. Hamilton, Ontario, Canada: McMaster University; 1992.
21. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233. doi:10.1097/05650-196030-03 PubMed (Pubitemid 126433231)
22. Vernon MK, Revicki DA, Awad AG, et al. Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res. 2010;118(1-3):271-278. doi:10.1016/j.schres.2010.01.021 PubMed
23. Citrome L. Treatment-refractory schizophrenia: what is it and what has been done about it? Neuropsychiatry. 2011;1(4):325-347. doi:10.217/npy.1.35
24. Burton SC. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use. J Psychiatr Pract. 2005;11(6):369-378. doi:10.1097/0131746-20510-03 PubMed (Pubitemid 41690416)
25. Essock SM, Schooler NR, Stroup TS, et al; Schizophrenia Trials Network. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011;168(7):702-708. doi:10.176/api.ajp.201.1060908 PubMed
26. Glick ID, Correll CU, Altamura AC, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72(12): 1616-1627.
27. Kraemer HC, Glick ID, Klein DF. Clinical trials design lessons from the CATIE study. Am J Psychiatry. 2009;166(11):1222-1228. doi:10.176/api.ajp.209. 08121809 PubMed
28. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry. 2007;68(suppl 6):5-9. PubMed (Pubitemid 47026640)
29. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93. doi:10.1093/schbul/sbp16 PubMed
30. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008;69(7):1046-1056. doi:10.408/JCP.v69n0702 PubMed (Pubitemid 352031586)
31. Stroup TS, Lieberman JA, McEvoy JP, et al CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4):611-622. doi:10.176/api.ajp.163.4.61 PubMed (Pubitemid 44464570)
32. Casey DE, Carson WH, Saha AR, et al; Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166(4):391-399. PubMed (Pubitemid 36469941)
33. Su J, Barr AM, Procyshyn RM. Adverse events associated with switching antipsychotics. J Psychiatry Neurosci. 2012;37(1):E1-E2. doi:10.1503/jpn.1096 PubMed
34. Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry. 2000;61(11):833-840. doi:10.408/JCP.v61n105 PubMed
35. Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580-588. doi:10.408/JCP.v64n0514 PubMed (Pubitemid 36618289)
36. Weiden PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol. 2006;20(1):104-118. doi:10.17/026981050568 PubMed
37. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007; 68(suppl 6):10-13. PubMed (Pubitemid 47026641)
38. Edlinger M, Baumgartner S, Eltanaihi-Furtmüller N, et al. Switching between second-generation antipsychotics: why and how? CNS Drugs. 2005;19(1): 27-42. doi:10.2165/023210-20519010-03 PubMed (Pubitemid 40165155)
39. Bernardo M, Vieta E, Ruiz JS, et al. Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry. Rev Psiquiatr Salud Ment (Barc). 2011;4:150-168. doi:10.1016/j.rpsm.201.07.03
40. Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(5):567-620. doi:10.17/ 026981039123 PubMed
41. Falkai P, Wobrock T, Lieberman J, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, pt 2: long-term treatment of schizophrenia. World J Biol Psychiatry. 2006 (1):5-40. doi:10.1080/15629705048317 PubMed (Pubitemid 43878525)
42. Falkai P, Wobrock T, Lieberman J, et al; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, pt 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6(3): 132-191. doi:10.1080/15629705103090 PubMed
43. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice Guideline for the Treatment of Patients With Schizophrenia, Second Edition. Am J Psychiatry. 2004;161(2 suppl):1-56. PubMed
44. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599-1613. doi:10.1517/1465656.201.626767 PubMed